Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Amir Zia

Neurology Bowling Green, KY Medical Doctor

NPI 1952452583 CMS profile 43584

996 Wilkinson Terrace Suite A-7, Bowling Green, KY 42103

Open in the dashboard

General payments

$1,714

113 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Amir Zia of Bowling Green, KY is reported in the CMS Open Payments database as having received $1,714 across 113 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $132 7
2020 General $490 31
2019 General $1,092 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amir Zia
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Amir Zia were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Amir Zia Neurology median Middle half National median
2019 $1,092 $474 $118–$2,177 $163
2020 $490 $367 $82–$2,309 $114
2021 $132 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Novartis Pharmaceuticals Corporation $398 27 payments
  2. Teva Pharmaceuticals USA, Inc. $245 18 payments
  3. Amgen Inc. $229 11 payments
  4. Biogen, Inc. $217 13 payments
  5. EMD Serono, Inc. $216 17 payments
  6. ACADIA Pharmaceuticals Inc $53 3 payments
  7. Allergan Inc. $46 3 payments
  8. Lundbeck LLC $43 3 payments
  9. E.R. Squibb & Sons, L.L.C. $43 3 payments
  10. Alexion Pharmaceuticals, Inc. $32 2 payments
  11. Other $193 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $1,714 113 payments
Products named General payments · program years 2019–2021
  1. AIMOVIG $388 21 payments
  2. Rebif $196 16 payments
  3. TECFIDERA $192 12 payments
  4. Ajovy Central Nervous System $147 11 payments
  5. AJOVY Central Nervous System $98 7 payments
  6. KESIMPTA $83 4 payments
  7. GILENYA $80 7 payments
  8. TYSABRI $77 5 payments
  9. NUPLAZID $53 3 payments
  10. ZEPOSIA $48 3 payments
  11. Other $456 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

113 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record